955 related articles for article (PubMed ID: 22857268)
21. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
22. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
[TBL] [Abstract][Full Text] [Related]
23. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
[TBL] [Abstract][Full Text] [Related]
24. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels.
Orvieto R; Nahum R; Meltzer S; Liberty G; Anteby EY; Zohav E
Gynecol Endocrinol; 2013 Sep; 29(9):843-5. PubMed ID: 23802563
[TBL] [Abstract][Full Text] [Related]
25. GnRH-Agonist Ovulation Trigger in Patients Undergoing Controlled Ovarian Hyperstimulation for IVF with Stop GnRH-Agonist Combined with Multidose GnRH-Antagonist Protocol.
Orvieto R; Nahum R; Frei J; Zandman O; Frenkel Y; Haas J
Gynecol Obstet Invest; 2021; 86(5):427-431. PubMed ID: 34537779
[TBL] [Abstract][Full Text] [Related]
26. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
Atkinson P; Koch J; Ledger WL
Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
[TBL] [Abstract][Full Text] [Related]
27. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
[TBL] [Abstract][Full Text] [Related]
28. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
Ren J; Sha A; Han D; Li P; Geng J; Ma C
Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
[TBL] [Abstract][Full Text] [Related]
29. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
30. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
31. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
[TBL] [Abstract][Full Text] [Related]
32. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol.
Chen SL; Ye DS; Chen X; Yang XH; Zheng HY; Tang Y; He YX; Guo W
Hum Reprod; 2012 May; 27(5):1351-6. PubMed ID: 22419746
[TBL] [Abstract][Full Text] [Related]
33. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
[TBL] [Abstract][Full Text] [Related]
34. GnRH antagonist rescue of a short-protocol IVF/ICSI cycle and GnRH agonist triggering to prevent ovarian hyperstimulation syndrome: two case reports.
Bakas P; Boutas I; Giner M; Panagopoulos P; Aravantinos L
Clin Exp Obstet Gynecol; 2017; 44(2):279-282. PubMed ID: 29746040
[TBL] [Abstract][Full Text] [Related]
35. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
36. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.
Griesinger G; von Otte S; Schroer A; Ludwig AK; Diedrich K; Al-Hasani S; Schultze-Mosgau A
Hum Reprod; 2007 May; 22(5):1348-52. PubMed ID: 17303632
[TBL] [Abstract][Full Text] [Related]
37. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
[TBL] [Abstract][Full Text] [Related]
38. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
39. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
40. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT).
Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Alexopoulou E; Kolibianakis EM
Hum Reprod; 2010 Mar; 25(3):683-9. PubMed ID: 20008886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
